Corpus overview


Overview

MeSH Disease

Human Phenotype

Arthritis (5)

Anxiety (2)

Pain (2)

Obesity (1)

Hypertension (1)


Transmission

Seroprevalence

There are no seroprevalence terms in the subcorpus

    displaying 1 - 5 records in total 5
    records per page




    The impact of the COVID-19 Pandemic on Patients with Chronic Rheumatic Diseases MESHD: A Study in 15 Arab Countries

    Authors: Nelly Ziade; Lina el Kibbi; Ihsane Hmamouchi; Nizar Abdulateef; Hussein Halabi; Wafa Hamdi; Fatemah Abutiban; Manal el Rakawi; Mervat Eissa; Basel Masri

    doi:10.21203/rs.3.rs-40892/v1 Date: 2020-07-09 Source: ResearchSquare

    Aim. To evaluate the impact of the Coronavirus Disease MESHD 2019 pandemic (COVID-19) on the access to rheumatology care for patients with chronic rheumatic diseases MESHD ( CRD MESHD) in the Arab countries.Method. A web-based cross-sectional survey was designed by the Arab Adult TRANS Arthritis HP Arthritis MESHD Awareness group (AAAA) consisting of 16 rheumatologists representing countries from the Arab League of Associations for Rheumatology (ArLAR), and was validated by the ArLAR scientific committee. The survey was disseminated through social media and patients' associations' channels between May 8 and May 22, 2020. The steering committee developed recommendations to improve the care of patients with CRD MESHD during the COVID-19 pandemic.Results. A total of 2163 patients were included in the analysis; 72% were females TRANS; mean age TRANS was 40 years (SD 11.9). The Levant, the Gulf, and North Africa contributed almost equally to the sample. The pandemic had a significant negative impact on rheumatology visits in 82% of cases, on access to hydroxychloroquine (47%), and on chronic medication persistency (28%). The negative impact on rheumatology visits was associated with female TRANS gender TRANS, country, medication non-persistency, isolation due to COVID-19, and impact on mental health. Sixty-one patients (2.8%) stated that they had COVID-19, 5% said that a close contact TRANS was infected, and 47% were in isolation because of COVID-19.Conclusion. The current study highlights the deleterious consequences of the COVID-19 pandemic on the continuity of rheumatology care. Therefore, an action plan, including establishing a telemedicine platform, securing drug availability, and promoting medication persistence through the appropriate communication channels, is strongly recommended.

    Clinical Outcomes of Patients with COVID-19 and Chronic Inflammatory and Autoimmune Rheumatic Diseases MESHD: A Multicentric Matched-Cohort Study

    Authors: José L Pablos; María Galindo; Loreto Carmona; Miriam Retuerto; Ana Lledó; Ricardo Blanco; Miguel A. González-Gay; David Martínez-López; Isabel Castrejón; José M. Alvaro-Gracia; David Fernández-Fernández; Antonio Mera-Varela; Sara Manrique-Arija; Natalia Mena-Vázquez; Antonio Fernández-Nebro; - RIER investigators group

    doi:10.1101/2020.06.18.20133645 Date: 2020-06-20 Source: medRxiv

    ABSTRACT Background The impact of inflammatory rheumatic diseases MESHD on COVID-19 severity is poorly known. Here we compare the outcomes of a cohort of rheumatic MESHD patients with a matched control cohort to identify potential risk factors for severe illness. Methods In this comparative cohort study, we identified hospital PCR+ COVID-19 rheumatic MESHD patients with chronic inflammatory arthritis MESHD arthritis HP (IA) or autoimmune/immunomediated diseases (AI/IMID). Non-rheumatic controls were randomly sampled 1:1, and matched by age TRANS, sex, and PCR date. The main outcome was severe COVID-19, defined as death MESHD, invasive ventilation, ICU admission, or serious complications. We assessed the association between the outcome and potential prognostic variables, adjusted by COVID treatment, using logistic regression. Results The cohorts were composed of 456 rheumatic MESHD and non-rheumatic MESHD patients, in equal numbers. Mean age TRANS was 63 [IQR 53-78] and male TRANS sex 41% in both cohorts. Rheumatic diseases MESHD were IA (60%) and AI/IMID (40%). Most patients (74%) had been hospitalised, and the risk of severe COVID was 31.6% in the rheumatic MESHD and 28.1% in the non-rheumatic cohort. Ageing, male TRANS sex and previous comorbidity ( obesity HP obesity MESHD, diabetes MESHD, hypertension HP hypertension MESHD, cardiovascular, or lung disease MESHD) increased the risk in the rheumatic MESHD cohort by bivariate analysis. In logistic regression analysis, independent factors associated with severe COVID were increased age TRANS (OR 5.31; CI 3.14-8.95), male TRANS sex (2.13; CI 1.35-3.36) and having an AI/IMID (OR 1.98; CI 1.15-3.41). Conclusion In patients with chronic inflammatory rheumatic diseases MESHD aging, sex and having an AI/IMID but not IA nor previous immunosuppressive therapies were associated with severe COVID-19.

    The impact of COVID-19 pandemic on pediatric rheumatology patients under immunosuppressive therapy: A single-center experience

    Authors: Oya Koker; Fatma Gul Demirkan; Gulsah Kayaalp; Figen Cakmak; Ayse Tanatar; Serife Gul Karadag; Emine Sonmez; Rukiye Omeroglu; Nuray Aktay Ayaz

    doi:10.21203/rs.3.rs-36583/v1 Date: 2020-06-19 Source: ResearchSquare

    Objective: The aim of the research was to further broaden current knowledge of whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease MESHD 2019 (COVID-19) entails a risk for children TRANS with rheumatic diseases MESHD regarding immunosuppressive treatment.Methods: Telephone-survey was administered by conducting interviews with the parents TRANS. A message containing a link to the actual questionnaire was sent to their phones simultaneously. The medical records of the patients were reviewed for gathering information about demographic data, clinical follow-up, and treatments.Results: Patients who were followed up with immunosuppressive treatment (n=439) were attempted to be contacted between 1 May 2020 and 15 May 2020. The diagnostic distribution of patients who were accessible and eligible for the study was as follows; juvenile idiopathic arthritis MESHD arthritis HP ( JIA MESHD) (n=243, 58.7%), autoinflammatory diseases MESHD (n=109, 26.3%), autoimmune connective tissue diseases (n=51, 12.3%) and vasculitis HP vasculitis MESHD (n=11, 2.7%). In the entire cohort, the mean age TRANS was 12 ± 4.7 years, and 54.1% (n=224) of the patients were female TRANS. One patient with seronegative polyarticular JIA MESHD, previously prescribed methotrexate and receiving leflunomide during pandemic has been identified to be diagnosed with COVID-19. None of the patients, including the patient diagnosed with COVID-19, had any severe symptoms. More than half of the patients with household contacts TRANS required hospitalization as they were asymptomatic TRANS.Conclusion: Although circumstances such as compliance in social distancing policy, transmission TRANS patterns, attitude following contact may influence the results, immunosuppressive treatment does not seem to pose additional risk in terms of COVID-19.

    The impact of eHealth group interventions on the mental, behavioural, and physical health of adults TRANS: A systematic review protocol

    Authors: Cheryl L Currie; Richard Larouche; M. L. Voss; Erin K. Higa; Rae Spiwak; David Scott; Treena Tallow

    doi:10.21203/rs.3.rs-37015/v3 Date: 2020-06-19 Source: ResearchSquare

    Background: COVID-19 has resulted in an increased demand for eHealth services globally. There is emerging evidence for the efficacy for group eHealth interventions that support population-based mental health and wellbeing, but a systematic review is lacking. The primary objective of this systematic review is to summarize the evidence for eHealth group counselling and coaching programs for adults TRANS. A second objective is to assess, within studies selected for our primary objective, the impact of programs that encourage PA on outcomes compared to those that do not.Methods: Randomized controlled trials that assess the impact of eHealth group counselling or coaching programs on mental health, health behaviour, or physical health activity among community dwelling adults TRANS will be included. We will search the following electronic databases (from January 2005 onwards): MEDLINE, PsycINFO, CINHAL, and the Central Register of Controlled Trials. The primary outcomes will be changes in mental health conditions (e.g. depression MESHD, anxiety HP anxiety MESHD, stress, quality-of life), behavioural health conditions (e.g. substance use, smoking, sexual behaviour, eating behaviour, medication adherence), and physical health conditions (e.g. coping with cancer MESHD, menopausal symptoms, arthritis HP arthritis MESHD pain HP). Secondary outcomes will be changes in physical activity. Two reviewers will independently screen all citations, full-text articles, and abstract data. Potential conflicts will be resolved through discussion with a third reviewer. A narrative synthesis without meta-analysis will be conducted. The strength of the body of evidence will be assessed using GRADE. The risk of bias in individual studies will be appraised using the Cochrane Risk of Bias 2.0 tool. Potential sources of gender TRANS bias in included studies will be considered at all stages of the planned review.Discussion: This review will contribute to the literature by providing evidence on the effectiveness of eHealth counselling and coaching programs delivered to adults TRANS in a group format. Systematic review registration: The protocol has been registered at the International Prospective Register of Systematic Reviews (PROSPERO: CRD42020187551).

    The impact of eHealth group interventions on the mental, behavioural, and physical health of adults TRANS: A systematic review protocol

    Authors: Cheryl L Currie; Richard Larouche; M. L. Voss; Erin K. Higa; Rae Spiwak; David Scott; Treena Tallow

    doi:10.21203/rs.3.rs-37015/v4 Date: 2020-06-19 Source: ResearchSquare

    Background: COVID-19 has resulted in an increased demand for eHealth services globally. There is emerging evidence for the efficacy for group eHealth interventions that support population-based mental health and wellbeing, but a systematic review is lacking. The primary objective of this systematic review is to summarize the evidence for eHealth group counselling and coaching programs for adults TRANS. A second objective is to assess, within studies selected for our primary objective, the impact of programs that encourage PA on outcomes compared to those that do not.Methods: Randomized controlled trials that assess the impact of eHealth group counselling or coaching programs on mental health, health behaviour, or physical health activity among community dwelling adults TRANS will be included. We will search the following electronic databases (from January 2005 onwards): MEDLINE, PsycINFO, CINHAL, and the Central Register of Controlled Trials. The primary outcomes will be changes in mental health conditions (e.g. depression MESHD, anxiety HP anxiety MESHD, stress, quality-of life), behavioural health conditions (e.g. substance use, smoking, sexual behaviour, eating behaviour, medication adherence), and physical health conditions (e.g. coping with cancer MESHD, menopausal symptoms, arthritis HP arthritis MESHD pain HP). Secondary outcomes will be changes in physical activity. Two reviewers will independently screen all citations, full-text articles, and abstract data. Potential conflicts will be resolved through discussion with a third reviewer. A narrative synthesis without meta-analysis will be conducted. The strength of the body of evidence will be assessed using GRADE. The risk of bias in individual studies will be appraised using the Cochrane Risk of Bias 2.0 tool. Potential sources of gender TRANS bias in included studies will be considered at all stages of the planned review.Discussion: This review will contribute to the literature by providing evidence on the effectiveness of eHealth counselling and coaching programs delivered to adults TRANS in a group format. Systematic review registration: The protocol has been registered at the International Prospective Register of Systematic Reviews (PROSPERO: CRD42020187551).

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.